AC
ALLO icon

AXQ Capital’s Allogene Therapeutics ALLO Stock Holding History

AXQ Capital’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173K Buy
83,217
+9,287
+13% +$20.4K 0.02% 743
2026
Q1 		$180K Buy
+73,930
New +$148K 0.02% 775
2023
Q2 		– Sell
-16,750
Closed -$82.7K – 280
2023
Q1 		$82.7K Sell
16,750
-56,302
-77% -$361K 0.03% 458
2022
Q4 		$459K Buy
+73,052
New +$676K 0.32% 105

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

AXQ Capital's ALLO Position: Q2 2026 in Review

AXQ Capital increased its Allogene Therapeutics (ALLO) stake by 13% in Q2 2026, buying an estimated $20.4K and bringing the position to 83,217 shares worth $173K. The position accounts for 0.02% of the portfolio, ranked #743.

AXQ Capital first reported a position in ALLO in Q4 2022 and has held it in 4 quarters since. The position peaked at $459K in Q4 2022. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • AXQ Capital held 83,217 shares of Allogene Therapeutics worth $173K as of Q2 2026.
  • AXQ Capital bought 9,287 Allogene Therapeutics shares in Q2 2026, an estimated $20.4K.
  • Allogene Therapeutics made up 0.02% of AXQ Capital's portfolio in Q2 2026, its #743 holding.
  • AXQ Capital first reported a position in Allogene Therapeutics in Q4 2022 and has held it in 4 quarters since.
  • AXQ Capital's Allogene Therapeutics position peaked at $459K in Q4 2022.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.